Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
Diabetic Male and Female Volunteers Needed for Exercise Research Study 06-0062
Evaluate exercise function during single leg calf exercise in people with or without type 2 diabetes
Healthy Adults 30-70 with Type 2 diabetes but not using insulin.  Must be a non-smoker who exercise no more than one time per week and have a BMI of 25-40
PI: Regensteiner, Judith
  • 303-724-2255
  • shawna.mcmillin@ucdenver.edu
Trouble Controlling your Type 2 Diabetes? 12-1529
Investigational non-surgical device that may help decrease blood sugar.
Adults 21-65 with type 2 Diabetes and not on oral medication, not taking insulin. Must have an A1C level of 8-10%, be overweight or obese and willing to attend study visits
PI: Wyatt, Holly
  • GI Dynamics
  • Jeanneanne.breen@ucdenver.edu
Project Safe - THE IMPACT OF MEDICAL MARIJUANA IN METROPOLITAN DENVER 11-0718
To learn more about the medical marijuana industry in Colorado and its relationship to health risk behaviors and healthcare.
Persons 18+ currently a medical marijuana patient or currently using non-medical marijuana
PI: Booth, Robert
  • 1-800-429-9240
  • Eric.Kovalsky@ucdenver.edu
Persons with active, moderate to severe ulcerative colitis needed 12-1408
This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.
Inclusion: Ages 18-70 Ulcerative colitis has been diagnoses by routine criteria At least one of the following applies: steroid dependent failed 5-ASA (mesalamine) therapy, such as Asacol Failed/lost response to infliximab (Remicade) Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (purinethol) therapy Exclusion (partial): Existing pregnancy, lactation, or planned pregnancy (men and women)
PI: Gerich, Mark
  • 303-724-7875
  • katelyn.cowan@ucdenver.edu
3D Gait Analysis Participants Needed 13-1857
Research study investigating the coordination of walking
Subject with Spastic Cerebral Palsy Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Retrospective gait data must contain a complete lower body marker set and valid kinetic data. ● Only gait data trials of the subject walking unassisted will be used. ● Diagnosis of spastic cerebral palsy. ● Exhibits either stiff knee gait pattern, characterized by insufficient and delayed peak knee flexion during swing (less than 45), or crouch gait pattern, characterized by excessive hip flexion and knee flexion (greater than 30 throughout stance). Cerebellar Ataxic Gait Subject Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Diagnosis of either Friedreich's or spinocerebellar ataxia. Subject with Lower Limb Amputation Inclusion Criteria: ● Males and females between the ages of 7 and 100 years of age. ● Ability to walk continuously and unassisted for 3 minutes. ● If under the age of 18, parent consent and subject assent. ● Has been using the prosthetic limb for at least 6 months for independent ambulation prior to gait analysis at CGMA. ● Below knee or above knee amputation.
PI: Worster, Kate
  • 720-777-8216
  • worsterk@gmail.com
Would you like to participate in a study to improve the understanding of how emotions and symptom distress affect adherence to hormonal therapy in breast cancer? 13-0371
The purpose of this study is to understand how emotional factors and symptom distress affect adherence to hormonal therapy in women that have completed all other treatment for breast cancer.   
Women Breast Cancer Survivor Age 21-70 years old Within 24 months of starting hormonal therapy: Aromatase Inhibitors or Tamoxifen (Aromatase Inhibitors, Exemestane (aromasin), Letrolzole (Femara), Anastrozole (Arimidex).
PI: Grossman, Vicki
  • 720-352-3316
  • Vicki.Grossman@ucdenver.edu
Do you spend most of your day sitting? WIRB #20131967
The Anschutz Health & Wellness Center is seeking participants for a new research project to determine if exercise performed throughout the day is more energizing compared to exercise performed in the morning or if you do not exercise.
Participants must meet the following criteria: - Sedentary - Between the ages of 25 - 50 - BMI between 18.5 and 29.9 kg/m^2 - Non-smoker
PI: Hill, James
  • 303-724-8299
  • Eats.Study@ucdenver.edu
Pharmacokinetics Research Study of Nontuberculous Mycobacteria Antibiotics in HEALTHY people and in people with CYSTIC FIBROSIS 14-1043
We are conducting a research study to test if levels of antibiotics used to treat nontuberculous mycobacteria infections are different between people with and without cystic fibrosis. The goal of our study is to provide recommendations for treatment of CF patients with lung disease due to nontuberculous mycobacterial infection.
Teenagers and adults who are either healthy or who have cystic fibrosis and are 16 to 45 years old may be eligible to participate in this study.
PI: Martiniano, Stacey
  • 720-777-2945
  • Meg.Anthony@childrenscolorado.org
Have the Flu? Living with a chronic medical condition, too? 11-0101
Influenza (the flu) can be life-threatening. Approximately 24,000 people in the United States die each year of this disease. We are conducting a study to determine whether treating patients with a combination of several drugs instead of just one helps them to get better faster.
You qualify for our study if you: •Have been diagnosed with the flu •Are at least 18 years of age •Have an existing medical condition that puts you at increased risk for complications from the flu—conditions such as diabetes; heart, lung, and kidney disease; COPD; and asthma
PI: Barron, Michelle
  • 303-724-0712
  • Graham.Ray@ucdenver.edu
Healthy Postmenopausal Women Needed for Cardiovascular Research Study 14-0532
The purpose of this study is to investigate how the health and function of arteries respond to estrogen, resveratrol, and exercise.
Postmenopausal women between the ages of 50-70 years, nonsmokers, not currently taking hormone replacement therapy or exercising vigorously more than 2 days per week.
PI: Moreau, Kerrie
  • 303-724-7465
  • cemal.ozemek@ucdenver.edu
Would your child like to participate in groundbreaking research and earn money? 12-1587
We are looking for healthy controls to participate in a research study investigating the cause of idiopathic scoliosis in adolescents.
Girls, 11-12 years old, do not have scoliosis or any other skeletal disorders, a BMI under 20 kg/m2, have not yet started their period, and have no family history of scoliosis
PI: Hadley Miller , Nancy
  • 720-777-4626
  • robin.baschal@childrenscolorado.org
Do you or someone you know have a food allergy to soy? 14-0097
We are studying the accuracy of a food allergy blood test.  
-Are age 1 to 21 and -Do have an IgE level greater than 0.35 to wheat OR soy or -Have had a positive skin test to wheat OR soy or -Have a clinically diagnosed wheat OR soy allergy -Do NOT use >500 micrograms/day fluticasone or equivalent -Do NOT have severe asthma, daily oral steroid dosing, or asthma requiring hospitalization within a year or an ER visit in the past 6 months -Do NOT have active EoE (or recently diagnosed) -Have NOT used biologic or allergen immunotherapy within the past year
PI: Fleischer, David
  • 720-777-2569
  • Hannah.Gilbert@childrenscolorado.org
Participants Needed For Research on Military Veterans And Service Dogs 14-2041
The purpose of this study is to explore the relationship between military veterans and their service dogs. Veterans will participate in one on one interviews.
Are you a military veteran? Do you have a service dog? Are you 18-89 years old? If you answered yes to the above, contact C-P.A.W.W. today.
PI: Krause-Parello, Cheryl
  • (303)-724-8282
  • CPAWW@ucdenver.edu
Are you taking medications for diabetes and resulting kidney complications? 13-1419
To evaluate a new investigational drug for people with Type 2 diabetes and kidney disease.
Person 18+ who are not of child bearing potential (f female) with type 2 diabetes and currently taking medication for kidney disease. You must be able to attend at least 6 office visits over 16 weeks.
PI: Rasouli, Neda
  • 720-848-7174
  • T2DMresearch@ucdenver.edu
MS Volunteers Needed for Research Study 12-1388
Looking to see if there is a cognitive improvement with the treatment of oral estriol as compared to oral placebo.
We are looking for: • Women 18-50 years old • Diagnosed with definite relapsing-remitting, secondary-progressive multiple sclerosis or primary-progressive multiple sclerosis • MS disease duration of 15 years or less • On stable dose of standard MS treatment with Copaxone®, Betaseron® (or Extavia®), Rebif®,Avonex®, Gilenya®, Aubagio®, Tecfidera®, or no treatment ----You are not eligible for the study if you are pregnant, breast-feeding, smoke, or have other serious medical conditions.
PI: Corboy, John
  • Brittany Kling
  • Brittany.Kling@ucdenver.edu
Apoyo con Cariño: Improving Palliative Care for Latinos with Cancer 12-0592
We want to understand if a patient navigator can help Latino patients and their family caregivers deal with cancer. Our project hopes to improve palliative or comfort care to patients with advanced cancer. The goal is to prevent or relieve suffering for people facing serious illness. Research is needed to find out if a patient navigator can help patients and family caregivers.
Adults (18 years and older) who self-identify as Latino and have Stage III-IV cancer.
PI: Fischer MD, Stacy
  • 303-724-7410
  • danielle.kline@ucdenver.edu
Seeking Adults with NO History of Eczema, Allergies or Asthma HS-2581
The purpose of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
Males and females between 18 and 64years of age with no history of Allergies, Eczema, or Asthma
PI: Leung, Donald
  • 303-270-2222
  • lairsmithj@njhealth.org
SPIROMICS-Subpopulations and Intermediate Outcome Measures in COPD Study HS-2678
To identify subpopulations of COPD patients in order to develop newer and more effective treatments and to clearly define measureable end points so that treatment effects may be accurately assessed in a shorter period of time.
Be willing to undergo study procedures Be between the age of 40 and 80 years old Have smoked fewer than one pack of cigarettes per day for one year OR have smoked more than one pack of cigarettes per day for 20 years
PI: Bowler, Russell
  • 303-270-2827
  • HerrudT@njHealth.org
Psychiatric Medication Study 11-0965
We are looking for volunteers to participate in a research study investigating how psychiatric medications are processed in people who are diagnosed with HIV-1 compared to subjects who are on psychiatric medications who are HIV-negative. You can participate in this study if you are HIV negative and taking certain psychiatric medications.
To Qualify: Must between the ages of  2 to <25 years; Be HIV-Negative; On a steady dose of Psychiatric Medication (Celexa, Lexapro, Risperdal, Zoloft, Prozac, Paxil or generic equivalents)
PI: McFarland, Elizabeth
  • 720-777-6257
  • jenna.wallace@childrenscolorado.org
HEALTHY MEN AND WOMEN 60-85 YEARS OLD Wanted to participate in a research study 13-2594
To test whether interrupting prolonged sitting with short bouts of moderate intensity walking can improve health
We are looking for men and women who:  Are age 60-85 years old  Healthy – no diagnosed disease  Not on glucose lowering medication  Do not participate in regular exercise  Ambulatory – able to walk without assistance  Are non-smokers
PI: Lyden, Kate
  • Kate Lyden
  • kate.lyden@ucdenver.edu
Healthy Female Adolescents Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 21 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Healthy Females needed! Ages 11 to 29 07-0816
For brain imaging research study on how the brain works with we taste sweets or receive money.  Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 11 to 29 who are right-handed, free of medication with no serious medical condition or permanent metal implants or braces/retainers.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
We are looking for Healthy Women to participate in a research study on.....Females, Aging, Metabolism, and Exercise (FAME) 12-1157
To examine the role that female sex hormones play in metabolism, energy expenditure, physical activity and chronic disease.
Healthy women 40-60 who have regular menstrual cycles and using no hormonal contraceptives
PI: Kohrt, Wendy
  • 720-848-6399
  • Kimberly.Harner@ucdenver.edu
Diabetes? 12-0923
To evaluate study medication for Type 2 Diabetes.
Person 18+ diagnosed with Type 2 Diabetes
PI: Rasouli, Neda
  • 720-848-7174
  • T2DMresearch@ucdenver.edu
Do you have Diabetes? 13-0131
To find the best combination drug treatment for type 2 diabetes
Persons who have had diabetes for less than 5 years and metformin is the only diabetes medication you are taking.
PI: Rasouli, Neda
  • 720-848-7174
  • Bradley.wine@ucdenver.edu
Type 1 Diabetes Research Study 11-0693
To study the effects of an FDA-approved medication on metabolism and blood vessel function.
Person 25-50 with type 1 diabetes who exercise vigorously less than four times per week and have normal blood pressure
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
CHILDHOOD and ADOLESCENT MIGRAINE PREVENTION STUDY 12-0776
to test two medicines for migraine prevention in children and teens. We want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency.
Children 8-17 who have migraine headaches
PI: Kedia, Sita
  • 720-777-8588
  • headacheresearch@childrenscolorado.org
Volunteers are invited for a research studying looking at pain in knee osteoarthritis 12-1188
To better understand the complex experience of pain for people with knee osteoarthritis
Persons 50 or older who have been diagnosed with knee osteoarthritis
PI: Stevens-Lapsley, Jennifer
  • 303-724-9590
  • kneepain@ucdenver.edu
Just received VARIVAX, the chickenpox vaccine? 13-2122
Research study looking at the immune response to chickenpox vaccine
Age 12 months to 50 years; able to enroll in study within 10 days of vaccination.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
Healthy Women Needed for Cardiovascular Research Study 06-0537
The purpose of this study is to investigate how the menopause transition and the loss of estrogen impacts the health and function of arteries in women.
- Premenopausal women 18-49 years, Perimenopausal women 40-55 years and Postmenopausal women 45-70 years - Non-smokers - Volunteers should NOT be taking Birth Control or Hormone Replacement Therapy (HRT) or exercising vigorously more than 2 days per week.
PI: Moreau, Kerrie
  • 720-848-6419
  • shape.study@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee. Sponsor Protocol No. 8-01. WIRB Protocol No.20100579
McCarty, Eric12-0796
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. WIRB Protocol No. 20140064
Lewis, Karl13-3079
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd- Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)(SELECT-2) Sponsor Protocol No. D1532C0064 WIRB Protocol No. 20121812
Oton, Ana14-0084
A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Sponsor Protocol No. EMR-63325-021. WIRB Protocol No. 20140155
Oton, Ana14-0085
A RANDOMIZED, DOUBLE-BLIND TRIAL ASSESSING THE IMPACT OF METHOTREXATE DISCONTINUATION ON THE EFFICACY OF SUBCUTANEOUS TOCILIZUMAB WITH METHOTREXATE THERAPY. Sponsor Protocol No. ML28776. WIRB Protocol No. 20132070
Striebich, Christopher14-0087
Evaluation of Potential Allergenicity of New Soybean Varieties Sponsor Protocol No. Monsanto Soy Allergen WIRB Protocol No.20131161
Fleischer, David14-0097
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors. Sponsor Protocol No. PT-112-101. WIRB Protocol No. 20140867
Camidge, David14-0151
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors. Sponsor Protocol No. M14-237. WIRB Protocol No.20140725
Weekes, Colin14-0251
Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis. Sponsor Protocol No. CFTY720D2306E1. WIRB Protocol No. 20140779
Corboy, John14-0289


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more